Cancer Research UK - Genetic switch for cancer cells’ immortality revealed
Scientists have revealed how a genetic switch involved in the packaging of DNA may be key to a cancer cell’s ability to keep growing.
The Francis Crick Institute (link is external) researchers, part-funded by Cancer Research UK, found that production of a protein called H1.0 was frequently switched off in many cancer types and that reactivating this protein halted tumour growth.
Studying cancer cells lacking H1.0, they found that DNA becomes uncoiled at key points, activating a series of genes that stall the cell in an ‘immature’ state. This allows the cells to carry on dividing and expanding the tumour.
But as the tumour grows H1.0 can spontaneously become switched back on in some cells. The researchers traced this back to a region of the DNA that acts as the control switch for H1.0 production. With H1.0 back up and running, the genes needed for the cell to keep on dividing are shut down again, returning it to a normal finite lifespan.
The Crick team are now searching for drugs that could speed up this process by kick-starting H1.0 production throughout the tumour. This could potentially provide an effective way of halting tumour growth across a range of tumour types.
Dr Paola Scaffid i(link is external), a research group leader at the Crick and part-funded by Cancer Research UK, said: “This research opens up the possibility of one day turning harmful tumours into benign ones by reverting cancer cells back to a finite lifespan, which would eventually cause the tumour to stop growing. Importantly, we’ve shown that patients whose tumours had low levels of H1.0 tend to do worse and that this was apparent across a range of cancers.
“We now know where to start looking for drugs that work by revoking cancer cells’ immortality, rather than just killing them off.”
Eleanor Barrie, Cancer Research UK’s senior science information manager, said: “Drugs targeting the way cancer cells disrupt gene activity by altering how DNA is packaged are an exciting new avenue of research, with some treatments entering trials for leukaemia patients. This intriguing study is one of the first to suggest how this approach could work in solid tumours and adds another layer to our understanding of the different types of cells that make up a tumour.”
Read more about this research here on our blog.
For media enquiries please contact the Cancer Research UK press office on +44 203 469 8300 or, out-of-hours, the duty press officer on +44 7050 264 059.
Notes to Editor
* Cristina Morales Torres et al., The linker histone H1.0 generates epigenetic and functional intratumour heterogeneity, Science (2016), DOI: 10.1126/science.aaf1644
Latest News from
Age UK comments on Dispatches investigation into Bupa care homes20/06/2017 12:35:00
Age UK has commented on the Channel 4 Dispatches programme from Monday 19 June 2017, 'Bupa Care Homes Undercover'.
Care system 'buckling' says Age UK as major care homes investigation launches15/06/2017 10:35:00
A recent study into the quality of care homes which has sparked a much wider legal investigation has been called 'a manifestation of our buckling social care system' by Age UK.
Diabetes UK - Brits failing to meet the recommended daily allowance of fruit and veg13/06/2017 09:35:00
A new survey* commissioned by Diabetes UK to promote its Food you love healthy eating campaign in Diabetes Week (Sunday 11 June to Saturday 17 June), has found that 66 per cent of adults eat three or fewer portions of fruit and/or vegetables a day – well below the recommended five portions - and 46 per cent won’t eat any fruit at least three days a week.
CRUK - Combining immunotherapies could benefit some aggressive breast cancers09/06/2017 10:15:00
Using two immunotherapy drugs together could help treat some patients with an aggressive form of breast cancer, according to an Australian study.
CRUK - Two clinical trials show promise with different targeted drugs for lung cancer07/06/2017 14:10:00
Two drugs targeting different gene faults in lung cancer have shown potential to be better than those already available, according to unpublished clinical trials.
CRUK - New chemotherapy approach offers breast cancer patients a better quality of life07/06/2017 12:10:00
The chemotherapy drug capecitabine gives patients a better quality of life and is as effective at preventing breast cancer from returning as the alternative regimen called CMF, when given following epirubicin.
CRUK - Adding abiraterone to standard treatment improves prostate cancer survival by 40 per cent06/06/2017 10:35:00
Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37 per cent, according to the results of one of the largest ever clinical trials for prostate cancer presented at the 2017 ASCO Annual Meeting in Chicago and published in the New England Journal of Medicine on Saturday.
British Red Cross - Manchester attack – What happens after05/06/2017 16:15:00
An edition of the BRC’s Newsthink encourages young people to consider ways that the public helped each other after the explosion. It also explores the role of practical help and emotional support during and after an emergency.